Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company. Pepticom’s disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being. Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.

Accelerating genomics research with machine learning and cloud tools. Zero setup up time for any scale of Bioinformatics analysis. Fully automated with powerful reports.

Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects.

Developing and applying innovative computational approaches to genomics for drug target discovery and precision medicine.

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

Provider of AI-aided drug discovery solutions designed to increase company value, accelerate research, and reduce costs for Pharma SMEs and academic institutions. The company offers a platform called Drug Engine, which integrates AI, data science, and collaboration tools to facilitate early drug discovery research. The entity consists of experts in drug discovery, AI, and bioinformatics.

NonExomics, Inc is a scientists-led company that has pioneered the discovery process of the new wave of targets from the so-called Dark Genome. Over the last 8 years, we have meticulously developed AI-based algorithms deployed on the patient data at a population scale, to discover over 250,000 new proteins and investigated their disruptions in over 1365 human diseases. We have performed extensive in silico and experimental validation on these new targets to develop them as diagnostics and therapeutics. Our target portfolio serves as a parallel universe in drug discovery that is ripe to be challenged by the available therapeutic modalities in various diseases. We welcome opportunities to collaborate with other partners in challenging these newly-found genes using small molecules, antisense oligos, antibodies, gene therapy, etc.

OpenDNA has created a cloud based precision genomic medicine platform for cardiovascular disease and diabetes that uses AI algorithms to predict risk and provide personalized treatments to patients. We believe the future of medicine is using data to improve patient outcomes and to reduce healthcare costs

Pinnacle Software, LLC is a global SaaS healthcare technology company providing market-leading Genomics, Healthcare, Insurance, and Life Science solutions in 59 countries and all 50 states. Pinnacle Software uses Genomic Artificial Intelligence, Quantum Computing, Data Science, Robotic Process Automation and Blockchain technologies to advance the future of healthcare and drive precision medicine. Industries we serve: GENOMICS - Pinnacle gives you the data and tools you need to make discoveries, diagnose diseases, and develop NGS applications. Pinnacle provides a canonical interface to over 1.5 quintillion data points and Genomic Artificial Intelligence to drive precision medicine. Primary data analysis tools, quantum computing, cloud storage, biological interpretation and reporting tools combine to create actionable assets for biotechnology enterprises. PHYSICIANS/PAYERS - With newly emerging care and payment models, incentive realignment and the rise of consumerism — change is constant. We’re collaborating with healthcare’s leaders to enable a new model of health and improve people’s lives. Count on us to help you convert data into actionable insights, achieve higher levels of automation and efficiency, innovate new products and services, modernize infrastructure, and deliver better outcomes at a sustainable cost. LIFE SCIENCES - Improve health outcomes, drive innovation, and enhance efficiencies and business agility with help from Pinnacle. Pinnacle deploys intelligent technologies and on-demand expertise to drive precision medicine. Our partners in diagnostic labs and biopharma leverage our SaaS platform to extract complex biomedical data. By connecting specialists to real-time data, Pinnacle develops actionable information assets for life science enterprises. Visit Pinnacle Software on Baidu Tieba - http://tieba.baidu.com/f/user/passport?jumpUrl=https://pinnacle-software.com

Vindhya Data Science is an innovative data science company. We specialize in bioinformatics, genomics, machine learning, artificial intelligence, structural biology and the full spectrum of computational biology. We love data and enjoy solving challenging problems! Our goal, through data analysis and interpretation, is to facilitate biological and drug discovery insights resulting in impactful decision making.

MY NEXT HEALTH Medical science has made tremendous progress in determining the links between single genes and disease outcomes. My Next Health examines the complexities of how many genes work together in concert with internal and external factors called epigenetics. We are a B2B company focused on the key human gene variations powering cellular pathways that impact human health. Our novel insights into genotype-phenotype associations have the potential to radically improve precision in healthcare and clinical trials.

Our mission is to help the life sciences field to develop and deploy health care products and services faster and better by developing innovative data-driven healthcare strategies. Our vision is to become a top-of-mind solution provider at an international level in this field. The health care industry is subject to wrong or inefficient diagnosis and therapeutic strategies. Difficulty to come with new efficient therapeutics and medical technologies have huge societal costs. This involves hospitals, laboratories, pharma/biotech, medtech, diagnostics, cell therapy, CROs, ... Strong trends consisting in hight pressure on budgets from health payers and patient empowerment also trigger a need for more tailored health care. The field is also under heavy data deluge (real-life, genomics, clinical, biology, demographics, … ) and adequate solutions need to be adopted to make the most out of these. Our approach is to use Data Science (Machine Learning, Statistics, Artificial Intelligence, Cloud Computing, Data Management, ...) to build new decision-support tools from public / private data to tackle these inefficiencies. We use this innovative approach on a rather traditional consulting model. Typical applications: - Clinical development - R&D - Diagnostics, prognostics, theranostics - Production and manufacturing excellence - Health policy-making - Patient care optimization A few numbers: - 2-digits growth every year since its inception. - Involved in ~30 scientific communications - More than half our turnover is made out of Belgium, a part of which out of EU. - Our machine learning library LiblineaR is downloaded worldwide >2000 times/month. - Our rheumatology platform rheumakit.com has >40.000 users/year.

Genuity Science is a wholly-owned subsidiary of US biotechnology company, HiberCell. Genuity Science is using world-leading genomics and machine learning to map the causal biology of disease and accelerate the development of better medicine. Our unique hybrid platform enables us and our partners to go from data to insights to impact with unrivaled power and efficiency, generating, validating and applying insights on virtually any disease to create novel drugs, diagnostics and tools for clinical care. Our capabilities span deeply phenotyped population genomics cohorts, CAP-accredited sequencing and comprehensive omics, world-renowned bioinformatics, and pioneering, validated and peer-reviewed AI/ML. Through our offices in Boston, Dublin and Reykjavik we put this platform to work for our global biopharma and life sciences partners and the patients they serve. To learn more, visit us at www.genuitysci.com.

PersMed Co., working on analyzing genomic data, with a specific focus on cancer, we are contributing to a field that has the potential to make a significant impact on healthcare. With the increasing availability of genomic data, we are able to study the underlying genetic causes of cancer in unprecedented detail, opening up new possibilities for the development of more effective treatments and prevention strategies. Our work involves analyzing large amounts of genomic data to identify patterns and anomalies that may be associated with cancer. By applying advanced statistical and machine learning techniques to this data, we can uncover important insights into the molecular mechanisms underlying cancer development and progression. Your research has the potential to lead to the development of new diagnostic tools and targeted therapies that can improve patient outcomes and quality of life. By understanding the genetic basis of cancer, we can develop more precise and personalized treatment options that are tailored to each patient's unique genetic profile. Overall, our work in analyzing genomic data for cancer research is an important contribution to the field of healthcare. With our expertise in data analysis and genomics, we are well-positioned to make significant contributions to the development of new cancer treatments and prevention strategies that can improve the lives of millions of people around the world.

StoneWise, founded in 2018, is a leading technology company dedicated to AI-driven novel drug discovery, and became a JLABS Singapore member company in 2024. Based on the GPT/Transformer framework and integrated with geometric deep learning algorithms, StoneWise has exclusively built a small-molecule drug design platform with a multimodal AI 3D molecular generation large model as the core. The company offers products and services for early-stage drug discovery to over 100 pharmaceutical enterprises and research institutions worldwide, covering molecular generation and design, customized model training, compound screening, and other related solutions. Leveraging its core technologies and platform, StoneWise currently has multiple in-house R&D pipelines that have advanced to the clinical trial phase.

Our project develops a computerized (in silico) approach to optimise the efficacy and precision of drug repurposing trials. De novo drug design requires 10 to 15 years until market entry. We want to help patients faster and more efficiently. In comparison to de novo drug design, drug repurposing can happen much faster, costs less, and imposes a lower risk. The time for validation of a known drug’s potential new purpose is significantly reduced because less or no animal experiments are required, clinical studies can be conducted sooner, potential side effects are already known. So far, finding a new use for an old drug (drug repurposing) has been a serendipitous process. REPO-TRIAL aims to improve the efficacy and precision of predicting new purposes for registered drugs by using a revolutionary in silico approach. We use computer-based algorithms and an innovative definition of diseases to screen for potentially beneficial effects of registered drugs in mechanistically related disease phenotypes. We then validate promising in silico-repurposed candidate drugs up to the clinical level. The algorithms that we use to identify mechanistically related disease phenotypes may include completely different organs or areas of the human body than the original was used for. This systems-based (integrative / whole-body) approach will create “virtual patient cohorts”. Finally, we will validate in silico repurposed drugs in actual clinical studies with real patients and high precision. Because validation of all new drug repurposing opportunities would be unrealistic, we will focus on a patient cohort that the REPO-TRIAL consortium understands very well (a) metabolic and cerebrocardiovascular disease phenotypes, such as stroke, diabetes or Alzheimer’s, or b) patients that are positive for a specific panel of diagnostic blood biomarkers that can be measured in the laboratory). REPO-TRIAL will provide rapid patient benefits, reduce drug development time & costs, and reduce risks.

Acutis Biosciences is a subsidiary Contract Research Organization (CRO) under the ownership of Acutis. At Acutis Biosciences, we are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics, and rewriting the rules to champion our biopharma partners. Our focus isn't just pioneering drug discovery and development; it's also forging an era of service excellence, setting a new standard in the industry to elevate precision medicine to another level. We specialize in enabling biopharmaceutical companies to discover biomarkers through advanced multi-omics analysis solutions powered by machine learning (ML) and artificial intelligence (AI). Our technology platforms in genomics and histopathology support our partners in development and validation of state-of-the-art cancer molecular diagnostic assays, in oncology, immuno-oncology and infectious diseases. Leading pharmaceutical and biotech companies trust us to deliver 11-star service coupled to extraordinary science. Learn more: www.acutisbiosciences.com

Reproducible -omics data interpretation, i.e. the derivation of actionable molecular biomarkers, is currently the main bottleneck in streamlined applications, obstructing the transformation of genomic information into insights for Biomedicine and Biotech. BioInfoMiner delivers unsupervized, fast and integrative interpretation of -omics experiments, in the form of biomarker signatures. Prioritized genes are mapped to few, clear, systemic pathways and phenotypes, enabling seamless biomarker identification and prioritization.

Worldwide, there are more than 20 million new cases of cancer each year. First-line therapies are not always the most effective and there is a strong need to move towards personalized medicine by offering the patients the best treatment as quickly as possible. This will help in increasing the chance or cure. Therefore, there is a need to improve the prediction of the response to treatments to be able to save patient’s lives and reduce the cost of expensive inefficient treatments. Our goal is to unlock the road to precision medicine by using multiomics, spatial data and AI.

Javelin Biotech creates predictive drug discovery platforms that merge human biology with computational biology to accelerate preclinical drug discovery and improve drug approval rates.

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

Developer of a platform based on protein and metabolomic marker discovery technologies. The company focuses on applying innovative multi-omics and artificial intelligence technologies to the screening, diagnosis and treatment of diseases, providing clients with products and services such as early screening of chronic diseases and cancer, medication guidance, recurrence monitoring, and new tumor drug research and development.

Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.

Our goal is to develop life-saving cancer therapies using cutting-edge science and machine learning.

DeepThink Health offers an innovative Precision Intelligence Platform that extracts, de-identifies and curates complex clinical, genomic and other contextual health datasets with unmatched accuracy and precision. Our platform transforms unstructured data into actionable intelligence at scale. DeepThink’s solutions then apply advanced analytics and proprietary machine learning to enable a variety of use cases across the healthcare spectrum. Our team has extensive experience and a track record of success in leading healthcare technology companies.